Advanced search
1 file | 263.92 KB

Quantitative detection of inhaled salmeterol in human urine and relevance to doping control analysis

Koen Deventer (UGent) , Oscar Juan Pozo Mendoza (UGent) , Frans Delbeke (UGent) and Peter Van Eenoo (UGent)
(2011) THERAPEUTIC DRUG MONITORING. 33(5). p.627-631
Author
Organization
Abstract
Salmeterol is a frequently prescribed beta(2)-agonist used for the treatment of asthma. Due to performance-enhancing effects of some beta(2)-agonists, salmeterol appears on the prohibited list published by the World Anti-Doping Agency and its therapeutic use is allowed but restricted to inhalation. Because the data on urinary concentrations originating from therapeutic use are limited, no discrimination can be made between use and abuse when a routine sample is found to contain salmeterol. Therefore, the urinary excretion of 100 mu g of inhaled salmeterol was investigated. A liquid chromatography-tandem mass spectrometry method was developed and validated for the quantification of urine samples. Sample preparation consists of an enzymatic hydrolysis of the urine samples followed by a liquid-liquid extraction at pH 9.5 with diethyl ether/isopropanol (5/1). Analysis was performed using selected reaction monitoring after electrospray ionization. The method was linear in the range of 0.5-50 ng/mL. The limits of quantification were 500 pg/mL. The inaccuracy ranged between 10.4% and -3.7%. Results show that salmeterol could be detected for 48 hours. The maximum urinary concentration detected was 1.27 ng/mL. Cumulative data showed that only 0.27% of the administered dose is excreted as parent drug within the first 12 hours. Analysis of 47 routine doping samples, declared to contain salmeterol during routine analysis, did not exhibit concentrations that could be considered originating from supratherapeutic doses.
Keywords
urine, mass spectrometry, doping, salmeterol, CHROMATOGRAPHY-MASS SPECTROMETRY, CLINICAL PHARMACOKINETICS, EQUINE URINE, BETA(2)-AGONISTS, CONFIRMATION, TERBUTALINE, METABOLISM, FENOTEROL, AGONISTS, detection

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 263.92 KB

Citation

Please use this url to cite or link to this publication:

Chicago
Deventer, Koen, Oscar Juan Pozo Mendoza, Frans Delbeke, and Peter Van Eenoo. 2011. “Quantitative Detection of Inhaled Salmeterol in Human Urine and Relevance to Doping Control Analysis.” Therapeutic Drug Monitoring 33 (5): 627–631.
APA
Deventer, Koen, Pozo Mendoza, O. J., Delbeke, F., & Van Eenoo, P. (2011). Quantitative detection of inhaled salmeterol in human urine and relevance to doping control analysis. THERAPEUTIC DRUG MONITORING, 33(5), 627–631.
Vancouver
1.
Deventer K, Pozo Mendoza OJ, Delbeke F, Van Eenoo P. Quantitative detection of inhaled salmeterol in human urine and relevance to doping control analysis. THERAPEUTIC DRUG MONITORING. 2011;33(5):627–31.
MLA
Deventer, Koen, Oscar Juan Pozo Mendoza, Frans Delbeke, et al. “Quantitative Detection of Inhaled Salmeterol in Human Urine and Relevance to Doping Control Analysis.” THERAPEUTIC DRUG MONITORING 33.5 (2011): 627–631. Print.
@article{2045131,
  abstract     = {Salmeterol is a frequently prescribed beta(2)-agonist used for the treatment of asthma. Due to performance-enhancing effects of some beta(2)-agonists, salmeterol appears on the prohibited list published by the World Anti-Doping Agency and its therapeutic use is allowed but restricted to inhalation. Because the data on urinary concentrations originating from therapeutic use are limited, no discrimination can be made between use and abuse when a routine sample is found to contain salmeterol. Therefore, the urinary excretion of 100 mu g of inhaled salmeterol was investigated. A liquid chromatography-tandem mass spectrometry method was developed and validated for the quantification of urine samples. Sample preparation consists of an enzymatic hydrolysis of the urine samples followed by a liquid-liquid extraction at pH 9.5 with diethyl ether/isopropanol (5/1). Analysis was performed using selected reaction monitoring after electrospray ionization. The method was linear in the range of 0.5-50 ng/mL. The limits of quantification were 500 pg/mL. The inaccuracy ranged between 10.4\% and -3.7\%. Results show that salmeterol could be detected for 48 hours. The maximum urinary concentration detected was 1.27 ng/mL. Cumulative data showed that only 0.27\% of the administered dose is excreted as parent drug within the first 12 hours. Analysis of 47 routine doping samples, declared to contain salmeterol during routine analysis, did not exhibit concentrations that could be considered originating from supratherapeutic doses.},
  author       = {Deventer, Koen and Pozo Mendoza, Oscar Juan and Delbeke, Frans and Van Eenoo, Peter},
  issn         = {0163-4356},
  journal      = {THERAPEUTIC DRUG MONITORING},
  keyword      = {urine,mass spectrometry,doping,salmeterol,CHROMATOGRAPHY-MASS SPECTROMETRY,CLINICAL PHARMACOKINETICS,EQUINE URINE,BETA(2)-AGONISTS,CONFIRMATION,TERBUTALINE,METABOLISM,FENOTEROL,AGONISTS,detection},
  language     = {eng},
  number       = {5},
  pages        = {627--631},
  title        = {Quantitative detection of inhaled salmeterol in human urine and relevance to doping control analysis},
  url          = {http://dx.doi.org/10.1097/FTD.0b013e318229c5f4},
  volume       = {33},
  year         = {2011},
}

Altmetric
View in Altmetric
Web of Science
Times cited: